JPWO2021194860A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021194860A5
JPWO2021194860A5 JP2022557087A JP2022557087A JPWO2021194860A5 JP WO2021194860 A5 JPWO2021194860 A5 JP WO2021194860A5 JP 2022557087 A JP2022557087 A JP 2022557087A JP 2022557087 A JP2022557087 A JP 2022557087A JP WO2021194860 A5 JPWO2021194860 A5 JP WO2021194860A5
Authority
JP
Japan
Prior art keywords
provisional patent
patent application
development
government
research
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022557087A
Other languages
Japanese (ja)
Other versions
JP2023518812A (en
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/023061 external-priority patent/WO2021194860A1/en
Publication of JP2023518812A publication Critical patent/JP2023518812A/en
Publication of JPWO2021194860A5 publication Critical patent/JPWO2021194860A5/ja
Pending legal-status Critical Current

Links

Description

連邦政府による資金提供を受けた研究開発の記載
本発明は、米国保健福祉省生物医学先端研究開発局によって授与された契約番号ＨＨＳＯ１００２０１８０００３６Ｃの下、政府の支援を受けて行われた。政府はこの発明における一定の権利を有している。
関連出願の相互参照
本出願は、2020年3月23日に出願された米国仮特許出願第62/993589号及び2020年4月17日に出願された米国仮特許出願第62/011,889号の利益を主張し、それらの全体が参照により本明細書に組み込まれる。
 Description of federally funded research and development
This invention was made with government support under Contract No. HHSO100201800036C awarded by the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services. The government has certain rights in this invention.
Cross-reference to related applications This application benefits from U.S. Provisional Patent Application No. 62/993,589, filed March 23, 2020, and U.S. Provisional Patent Application No. 62/011,889, filed April 17, 2020. and are incorporated herein by reference in their entirety.

JP2022557087A 2020-03-23 2021-03-19 Combination of tocilizumab and remdesivir to treat COVID19 pneumonia Pending JP2023518812A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062993589P 2020-03-23 2020-03-23
US62/993,589 2020-03-23
US202063011889P 2020-04-17 2020-04-17
US63/011,889 2020-04-17
PCT/US2021/023061 WO2021194860A1 (en) 2020-03-23 2021-03-19 Tocilizumab and remdesivir combination therapy for covid-19 pneumonia

Publications (2)

Publication Number Publication Date
JP2023518812A JP2023518812A (en) 2023-05-08
JPWO2021194860A5 true JPWO2021194860A5 (en) 2024-03-29

Family

ID=75581614

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022557087A Pending JP2023518812A (en) 2020-03-23 2021-03-19 Combination of tocilizumab and remdesivir to treat COVID19 pneumonia

Country Status (4)

Country Link
US (1) US20230174656A1 (en)
EP (1) EP4107186A1 (en)
JP (1) JP2023518812A (en)
WO (1) WO2021194860A1 (en)

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5670373A (en) 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
ES2134212T3 (en) 1991-04-25 1999-10-01 Chugai Pharmaceutical Co Ltd HUMAN ANTIBODY RECONSTITUTED AGAINST THE RECEIVER OF INTERLEUKIN 6 HUMAN.
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
ATE244763T1 (en) 1992-02-11 2003-07-15 Cell Genesys Inc ACHIEVEMENT OF HOMOZYGOTE THROUGH TARGETED GENETIC EVENTS
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
DE69830315T2 (en) 1997-06-24 2006-02-02 Genentech Inc., San Francisco GALACTOSYLATED GLYCOPROTEIN CONTAINING COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
ATE419009T1 (en) 1997-10-31 2009-01-15 Genentech Inc METHODS AND COMPOSITIONS CONSISTING OF GLYCOPROTEIN GLYCOFORMS
ATE375365T1 (en) 1998-04-02 2007-10-15 Genentech Inc ANTIBODIES VARIANTS AND FRAGMENTS THEREOF
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
ES2528794T3 (en) 2000-04-11 2015-02-12 Genentech, Inc. Multivalent antibodies and uses thereof
NZ592087A (en) 2001-08-03 2012-11-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
ES2326964T3 (en) 2001-10-25 2009-10-22 Genentech, Inc. GLICOPROTEIN COMPOSITIONS.
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
JP4364645B2 (en) 2002-02-14 2009-11-18 中外製薬株式会社 Antibody-containing solution formulation
EA036531B1 (en) 2003-11-05 2020-11-19 Роше Гликарт Аг Type ii anti-cd20 humanized antibody (variants), pharmaceutical composition comprising these antibody variants, and use thereof
PE20091174A1 (en) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd LIQUID FORMULATION WITH HIGH CONCENTRATION OF ANTIBODY CONTENT
TWI440469B (en) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
TWI698444B (en) 2014-10-29 2020-07-11 美商基利科學股份有限公司 Methods for the preparation of ribosides

Similar Documents

Publication Publication Date Title
CY1118714T1 (en) HIGH CONCENTRATION HUMAN CATALOGS IN THE PROTECTION-PROTECTED HUMAN RECEPTORS-2
CY1115257T1 (en) DESTROYED ANTI-IGE B membranes bound to membrane bound
WO2018190719A3 (en) Anti-sirp alpha antibodies
CY1119454T1 (en) ANTIBODIES AGAINST CD38 FOR TREATMENT OF MULTIPLE MYELOMA
EA201992131A1 (en) HIGH-AFFINE SPECIFIC TO MAGE-A1 TCR AND THEIR APPLICATION
CY1114271T1 (en) CLEANINGS, HUMAN CELLULAR PUMP, AND USE OF THESE
GEP20217253B (en) ANTIBODIES TO α-SYNUCLEIN AND USES THEREOF
CY1113160T1 (en) ARYLURIA COMPOUNDS IN CONNECTION WITH OTHER CELLULAR OR CELLULAR MEDICINES FOR HUMAN CANCER TREATMENT
ATE511551T1 (en) APTAMERS SELECTED FROM LIVING TUMOR CELLS AND THEIR USE
BR0011838B1 (en) saddle element and static mixer structure.
DE602004024037D1 (en) SUBSTITUTED HETEROCYCLES
ATE471334T1 (en) PHOSPHORAMIDATE DERIVATIVES OF NUCLEOSIDE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER
EA201170659A1 (en) ANTIBODIES TO TGF-VETA RECEPTOR II
BRPI0516661A (en) interleukin-21 antigenic epitopes, related antibodies and their use in the medical field
CO2022002001A2 (en) Therapeutic uses of anti-tcr delta 1 variable antibodies
JP2019522032A5 (en)
CY1122818T1 (en) 3-((HETERO-)ARYL)-ALKYL-8-AMINO-2-OXO-1,3-DIAZA-SPE1PO-[4.5]-DECANE DERIVATIVES
BR112021025699A2 (en) Anti-mesothelin antibodies and immunoconjugates thereof
EA202092085A1 (en) THERAPEUTIC ANTIBODIES AGAINST sPLA2-GIB AND THEIR APPLICATION
EA201891611A1 (en) DERIVATIVES 3 - ((HETERO-) Aryl) -8-AMINO-2-OXO-1,3-DIAZASPIRO [4,5] DEAN
DE602004017326D1 (en) TETRAHYDROCARBAZOL DERIVATIVES AND THEIR PHARMACEUTICAL USE
EA202092156A1 (en) MODIFIED OLIGONUCLEOTIDES AND METHODS OF APPLICATION IN TAUPATHY TREATMENT
WO2022183074A3 (en) Anti-psma antibodies and car-t structures
JPWO2021194860A5 (en)
NO20076663L (en) immunoglobulins